 Shares of BioXcel Therapeutics Inc. BTAI, -2.98 jumped 14.6 in premarket trading on Wednesday after the company said the Food and Drug Administration approved Igalmi, a sublingual film used to treat agitation associated with schizophrenia or bipolar disorder in adults. The therapy is expected to launch in the U.S. in the second quarter of this year. 